Press Releases

News Release - March 15, 2018
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

News Release - October 18, 2017
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

News Release - September 25, 2017
AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

News Release - July 20, 2017
AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program

In the Media

Companies pair up to take Rett Syndrome program into clinic - July 20, 2017


News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact - July 20, 2017


FDA Gives Fast Track Status to Potential Therapy for Congenital Myotonic Dystrophy - June 1, 2017


AMO Pharma receives FDA Fast Track Status - May 30, 2017

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford - May 30, 2017


AMO Pharma Addresses Rare Childhood Disease - May 22, 2017


Ranedis and AMO Partner to Develop HDAC Inhibitor for Rare Genetic Diseases - March 14, 2017


AMO Pharma and Ranedis target rare genetic diseases in RND-001 deal - March 14, 2017


Wayne-Based AMO Pharma Raises $25 Million - October 1, 2015


Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma - October 1, 2015

Stay updated about AMO! Enter your information here to receive updates about AMO Pharma via email:

To unsubscribe from all AMO Pharma communications, please click here.